Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Firms Commit To Local Production As Turkey Seeks Import Cuts

Executive Summary

The Turkish government’s drive to increase the local production of medicines has begun to yield results, with companies so far committing to shift over $500m in sales to domestic manufacture, as the country plans to cut around $685m from its drug imports bill in the first year of the program.

You may also be interested in...



New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.

New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.

Turkey: International Medtechs Demand Stable Pricing And On-Time Payments

Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel